A Retroviral Vector That Allows Efficient Co-Expression of Two Genes and the Versatility of Alternate Selection Markers
- 20 May 1997
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 8 (8) , 979-983
- https://doi.org/10.1089/hum.1997.8.8-979
Abstract
PZIG(hGCSFR) is a retroviral vector that can co-express two genes and also provides alternative selection markers. This retroviral vector has been constructed to incorporate an internal ribosome entry site (IRES) element to co-express two exogenous genes in mammalian cells. Two marker/selection genes have been cloned into the vector that not only allow the efficiency of co-expression to be quantified but also provide versatility of selection criteria. A cDNA encoding the hGCSFR (signaling deficient) was cloned as the 5′ cistron, and a gene encoding a neomycin-resistance and β-galactosidase (βgeo) fusion protein was cloned as the 3′ cistron. The two marker genes cloned in this retroviral vector allow the selection and isolation of mammalian cells following either transient (by fluorescence-activating cell sorting analysis of hGCSFR-positive cells) or stable (neomycin resistance) infection with the certainty that over 93% of clones will co-express both genes. This novel vector offers a versatile retroviral vector that can be potentially used in a wide range of gene therapy applications as the gene of interest can be coexpressed with either of the marker genes depending on whether the retroviral infection is to be performed in vitro, in vivo, or ex vivo.Keywords
This publication has 24 references indexed in Scilit:
- Tissue-Specific Targeting of Retroviral Vectors Through Ligand-Receptor InteractionsScience, 1994
- The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in ratsJournal of Neurosurgery, 1994
- Gene Therapy for CancerHuman Gene Therapy, 1994
- Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumorsJournal of Neurosurgery, 1993
- Gene Therapy for the Treatment of Brain Tumors Using Intra-Tumoral Transduction with the Thymidine Kinase Gene and Intravenous Ganciclovir. National Institutes of HealthHuman Gene Therapy, 1993
- Gene therapy of maliganant brain tumors: A rat glioma line bearing the herpes simplex virus type 1‐thymidine kinase gene and wild type retrovirus kills other tumor cellsJournal of Neuroscience Research, 1992
- Immunization of Cancer Patients Using Autologous Cancer Cells Modified by Insertion of the Gene for Interleukin-2 (National Institutes of Health)Human Gene Therapy, 1992
- Retroviral Gene Transfer Using Safe and Efficient Packaging Cell LinesAnnals of the New York Academy of Sciences, 1990
- Cap-independent translation of encephalomyocarditis virus RNA: structural elements of the internal ribosomal entry site and involvement of a cellular 57-kD RNA-binding protein.Genes & Development, 1990
- The murine interleukin-4 receptor: Molecular cloning and characterization of secreted and membrane bound formsCell, 1989